Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke — Director, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred
Biogen Inc.
-(BIIB)
XNAS:BIIB
Biogen, Inc. (BIIB) Q4 2020 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke -- Director, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Key financials of Biogen (BIIB) Q4 2020 earnings report
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in
Earnings calendar for the week of January 11
Stock markets responded positively to the latest developments in presidential election. On the heels of the Dow Jones Industrial Average achieving a
Biogen (BIIB) might need to revisit pipeline after Alzheimer’s drug setback
The controversy surrounding biotechnology firm Biogen's (NASDAQ: BIIB) Alzheimer's drug Aducanumab took a positive turn last week after the FDA issued a
Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q3 2020 earnings call dated Oct. 21, 2020 Corporate Participants: Joe Mara -- Head of Investor Relations Michel Vounatsos -- Chief Executive Officer
Biogen tops market estimates in Q3, lowers guidance
Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in
Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript
Biogen Inc. (NASDAQ: BIIB) Q2 2020 earnings call dated July 22, 2020 Corporate Participants: Joe Mara -- Vice President of Finance and Head of
Infographic: Key financials of Biogen (BIIB) Q2 2020 earnings report
Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted
Delay in filing Biogen’s Alzheimer’s drug leaves analysts scratching head during conference call
Late last year, Biogen (NASDAQ: BIIB) made an announcement that left investors gung-ho. The stock soared 27% after the company optimistically said
Biogen Inc (NASDAQ: BIIB) Q1 2020 Earnings Call Transcript
Biogen Inc (BIIB) Q1 2020 earnings call dated Apr. 22, 2020 Corporate Participants: Joe Mara -- Vice President, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Biogen (BIIB) Q1 2020 Earnings Results
Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today. Biogen posted a 1% decline in
Biogen Inc (NASDAQ: BIIB) Q4 2019 Earnings Call Transcript
Biogen Inc (BIIB) Q4 2019 earnings call dated Jan. 30, 2020 Corporate Participants: Joe Mara -- Vice President, Investor Relations Michel Vounatsos -- Chief Executive Officer
Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
Biogen (BIIB) earnings preview: Will stock bounce back after Q3 report?
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy
Top biotech stocks to be considered for investment this year
When the massive selloff battered Wall Street in the final months of 2018, biotechnology stocks were no exception. And, most of them
Spinraza helps Biogen beat the street in Q1
A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Biogen ends Alzheimer’s Phase 3 trials, stock plunges above 28%
Shares of the biopharma firms Biogen (NASDAQ: BIIB) and Eisai Co. Ltd (ESALY) plummeted above 28% and 34% respectively at 2 PM
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
ImmunoGen reports Q4 loss; stock gains as results beat estimates
Biotechnology firm ImmunoGen Inc. (IMGN) reported a wider net loss for the fourth quarter, hurt by a sharp fall in revenues. However,
Biogen’s Q4 results beat estimates; revenues up 7%
Biogen Inc. (BIIB) reported revenue and earnings that surpassed market expectations for the fourth quarter of 2018. The stock was up 1.16%